According to a new market report published by Persistence Market Research “Global Market Study on Osteoporosis Drugs: AsiaPacific to Witness Highest Growth by 2022”, the global osteoporosis drugs market is estimated to be valued at US$11,226.1 Mn by the end of 2015 and is expected to expand at a CAGR of 4.0% from 2014 to 2022, to account for US$14,786.7 Mn by 2022.
The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Prevalence of osteoporosis is high among people aged 60 years and above. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market.
The global osteoporosis drugs market is projected to exhibit sluggish growth by the end of 2031 with escalating demand for these drugs across the globe for the treatment of ailments such as prophylaxis. The wide range of pipeline drugs are expected to create new revenue prospects in the market.
Growing osteoporosis conditions bred by the sedentary lifestyle is expected to drive the adoption rate of these drugs in the coming years.
Strategizing The Moves For The Next Decade? See Through Sample Of Osteoporosis Drugs Market Report! https://www.persistencemarketresearch.co/samples/2983
Top companies profiled in this report are:
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Merck & Co, Inc.
- Novartis AG
- Amgen, Inc.
- Novo Nordisk A/S
- Actavis plc
- Pfizer, Inc.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd
Starting With The New Decade On A Diligent Note In The Osteoporosis Drugs Market? https://www.persistencemarketresearch.co/methodology/2983
However, there are various side effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits the growth of the market.The osteoporosis drugs market is anticipated to grow from an estimated US$11,226.1 Mn by the end of 2015 to account for US$14,786.7 Mn by 2022 at a CAGR of 4.0% during the forecast period.
In North America, the prevalence of osteoporosis is high primarily due to increasing geriatric population, growing obesity, and rising prevalence of lifestyle associated diseases in the region. According to the National Osteoporosis Foundation, in 2013, approximately 54 million people in the U.S. aged 50 years and above were affected by osteoporosis and low bone mass. According to the U.S. Department of Health and Human Services, in the U.S., approximately 250,000 hip fractures are associated with osteoporosis.
In Europe, increasing aging population, changing lifestyles, and increasing consumer awareness about osteoporosis care are driving the growth of the osteoporosis drug market. According to the International Osteoporosis Foundation, approximately 5.5 million men and 22 million women suffered from osteoporosis in 2010. Moreover, according to International Osteoporosis Foundation, approximately 27.5 million people in Europe suffered from osteoporosis in 2010 and the number is expected to reach 33.9 Mn by 2030.
How About Obtaining Insights About The Region To Enter Concerning The Osteoporosis Drugs Market? Press The “Purchase Now” Button To Have Our Osteoporosis Drugs Market Report! https://www.persistencemarketresearch.com/checkout/2983
However, the growth of osteoporosis market in Asia Pacific is much due to rising geriatric population and changing lifestyles in the region. Osteoporotic patients have a higher risk of hip fractures, owing to a major cause of morbidity and mortality.
According to the International Osteoporosis Foundation, by 2050, approximately 50% of the world’s osteoporosis hip fractures would occur in women in Asia. In addition, according to a study on Epidemiology in Osteoporosis in Japan by the National Centre for Biotechnology Information, in 2011, approximately 15 million people suffered from osteoporosis in Japan.
Access Trending Reports:
Ophthalmic Devices Market – The global ophthalmic devices market was valued at USD 29,171.5 million in 2014 and is expected to grow at a CAGR of 6.5% from 2014 to 2020, to reach an estimated value of USD 42,685.1 million in 2020.
Flavors Into Over The Counter Otc Pharmaceuticals Market – Preference for fruit flavors in medicines is an ongoing trend in the flavors into over-the-counter (OTC) pharmaceuticals market. The consumption of fruit flavor formulations by leading manufacturers is relatively high as compared to other flavors.
Prepackaged Medical Kits Trays Market – The concept of value-based pricing of pharmaceuticals has gained momentum in the last few years and a majority of the OECD countries have adopted this model. This shift has been a crucial component for the revenue growth of the pre-packaged medical kits and trays market.
About Us :-
Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.